Rain Therapeutics Inc. (NASDAQ:RAIN – Get Rating) Director Franklin M. Berger purchased 45,000 shares of the firm’s stock in a transaction on Monday, November 21st. The shares were purchased at an average cost of $7.80 per share, with a total value of $351,000.00. Following the completion of the purchase, the director now owns 928,207 shares in the company, valued at approximately $7,240,014.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Rain Therapeutics Trading Down 5.7 %
Shares of NASDAQ RAIN traded down $0.48 during mid-day trading on Thursday, reaching $8.00. The company had a trading volume of 122,771 shares, compared to its average volume of 89,060. The company has a 50-day moving average price of $5.78 and a two-hundred day moving average price of $5.17. The stock has a market cap of $212.56 million, a PE ratio of -2.99 and a beta of -0.33. Rain Therapeutics Inc. has a 1-year low of $2.15 and a 1-year high of $14.90.
Rain Therapeutics (NASDAQ:RAIN – Get Rating) last released its quarterly earnings results on Thursday, November 10th. The company reported ($0.68) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.01. On average, research analysts expect that Rain Therapeutics Inc. will post -2.43 EPS for the current year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
Several research analysts recently weighed in on RAIN shares. HC Wainwright raised their target price on Rain Therapeutics from $10.00 to $12.00 in a research note on Friday, November 11th. Citigroup reduced their price objective on shares of Rain Therapeutics from $30.00 to $29.00 and set a “buy” rating for the company in a research report on Wednesday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Rain Therapeutics has an average rating of “Buy” and a consensus target price of $17.29.
About Rain Therapeutics
Rain Therapeutics Inc, a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers.
- Get a free copy of the StockNews.com research report on Rain Therapeutics (RAIN)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Rain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.